Enrollment in Both Dose Cohorts of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Hypertrophic Cardiomyopathy (HCM) Complete; Follow-up Data...
Initiation of additional trial sites and patient enrollment activities ongoing with multiple patients in screening LAWRENCEVILLE, N.J., July 30, 2025...
KUALA LUMPUR, Malaysia, July 30, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (“BGLC”, Nasdaq: BGLC) and Fidelion Diagnostics Pte Ltd, a Singaporean company...
Leaders in pioneering cancer diagnostics and NGS target enrichment technologies join forces to accelerate access to advanced molecular diagnostics for...
The new cytometry technology enhances accessibility, safety, and efficiency in sperm-sorting procedures The acquisition of 18 cell-sorting systems and associated...
STUDIO CITY, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- Today, the International Myeloma Foundation (IMF) announces with great sadness the...
LAWRENCEVILLE, N.J., July 29, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its...
Mean signs and symptoms for participants in Stage 3 of the SAHARA trial remained statistically significantly better than study baseline...
- Novel once-weekly injectable VMAT2 inhibitor targets underserved patients with serious adherence and access challenges – - Potential expansion into...
New initiative makes joining the marrow registry as easy as chewing gum Awareness drive kicks off at the Mets game...
GAITHERSBURG, Md., July 28, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announces its recognition of the U.S....
Troculeucel, a cryopreserved autologous, non-genetically modified NK cell product, appears to cross the blood brain barrier (BBB) via CXCR3, to...
Stock Dividend Reflects Company’s Confidence in its Phase 3 Study, Long-term Growth Potential, and Dedication to Shareholders LAWRENCEVILLE, N.J., July...
Initial results demonstrate numerical improvement of cognitive and functional measures with inidascamine across both active treatment arms compared to placebo,...
Company to compete for “Science Breakthrough of the Year” at Europe’s leading deep-tech summit in Berlin, Germany this NovemberTORONTO and...
COPENHAGEN, Denmark, July 25, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered...
The Houston Business Journal's Most Admired CEO Awards recognize chief executive officers who exemplify exceptional leadership, vision and values while...
Results show biopsy-proven resolution of BK polyomavirus nephropathy in kidney transplant recipients No safety or tolerability concerns were observedSupports progression into...
Pending European Commission (EC) approval, Alhemo® will become available to all adult and paediatric patients 12 years and older living...
Results show biopsy-proven resolution of BK polyomavirus nephropathy in kidney transplant recipients No safety or tolerability concerns were observedSupports progression into...